The present invention relates, in part, to methods of preventing and/or treating a subject afflicted with bone loss conditions comprising administering to the subject a therapeutically effective amount of an agent that decreases the amount and/or activity of irisin.

Disclosed herein is an integrated microfluidic chip for detecting cancerous cells, particularly, cholangio-cancerous cells, from a biological sample. Also disclosed herein is a method of detecting cholangio-cancerous cells from a biological sample.

The present disclosure relates to a novel biomarker for use in human glioblastoma, namely to a compound inhibiting WNT6 biomarker for the treatment of glioblastoma; preferably proneural glioblastoma, classic glioblastoma, neural glioblastoma, or mesenchymal glioblastoma. The present disclosure also relates to a WNT pathway inhibitor for use in a method of treating glioblastoma, pharmaceutical compositions and a kit for use in the treatment of glioblastoma.

The present application relates to use of hexokinase-2 and a kit for detecting rare tumor cells in body fluid sample. The present application, based on a principle of abnormal tumor cell energy metabolism, conducts a vitro detection by using a glycolysis marker hexokinase-2 (HK2) as a marker, and assists localization and selection of the rare tumor cells by an addressable microporous array chip or a glass sheet, so as to implement a detection on rare tumor cells having high glycolysis activity in a cancer patient's body fluid sample. The detection method of present application allows to detect rare tumor cells having high glycolysis activity in the human body fluid sample, especially detect circulating tumor cells of an interstitial origin tumor and the circulating tumor cells having epithelial-interstitial transformation in epithelial origin tumors, thereby covering the shortage of traditional detection against the circulating tumor cells based on an epithelial marker, and providing a technical basis for better application of cancer liquid biopsy in clinic.

A method for detecting anti-deoxyhypusine synthase autoantibody in a subject, wherein the method includes detecting, in a blood, serum, or plasma sample from a test subject with digestive system cancer, the amount of anti-deoxyhypusine synthase autoantibody, wherein the autoantibody is able to bind to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

Disclosed are an EGFRvIII antibody and a conjugate, and a preparation method and the use thereof. The antibody comprises complementarity-determining regions (CDRs) of the EGFRvIII antibody: one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3, and/or one or more of light chain CDR1, light chain CDR2 and light chain CDR3, with the amino acid sequence thereof being as described in the present invention. The EGFRvIII antibody has a high affinity with the EGFRvIII protein, and can enter cells after coupling with small molecule toxins such as MMAE and has a cytotoxic killing effect on EGFRvIII positive cells. The antibody therefore can be used for preparing drugs for treating tumors and other diseases.

Methods and devices are provided for assessing biological samples using molecular analysis. In certain aspects, methods and devices of the embodiments allow for the collection of liquid tissue samples and delivery of the samples for mass spectrometry. In certain aspects, the results of the mass spectrometry can be analyzed to determine tissue type, sample quality, or disease state of the sample.

The present disclosure provides methods of treating a subject having urothelial cancer, and methods of monitoring the efficacy of neoadjuvant treatment in a subject having clinically localized urothelial cancer.

The present disclosure is related to systems and methods to be used as aids in the diagnosis of risk for oral cancer, potentially malignant oral lesion (PMOL), and/or oral epithelial dysplasia (OED) by identifying cellular phenotype characteristics of cell samples, including percentage of mature squamous cells, presence or absence of nuclear actin in mature squamous cells, percentage of non-mature squamous cells, percentage of small round cells, percentage of white blood cells, and percentage of lone nuclei.

The present invention relates to a nucleic acid molecule which encodes a splice variant of the human P2RX7 receptor, and nucleic acid molecules derived therefrom, a recombinant vector containing said nucleic acid molecules, a host containing said recombinant vector, a polypeptide encoded by said nucleic acid molecules, a host cell expressing said polypeptide, a binding molecule binding to said polypeptide, a pharmaceutical composition comprising said binding molecule, a method for the production of the isolated polypeptide, and other methods and uses in connection therewith.